# Abivax S.A.: overview ABVX · Nasdaq · CIK 1956827 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/abvx.md) · [Financials](/companies/abvx/financials.md) · [Filings](/companies/abvx/filings.md) · [Insiders](/companies/abvx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.75)](/filings/0001956827-24-000007.md) | [(3.18)](/filings/0001956827-25-000010.md) | [(3.43)](/filings/0001956827-26-000012.md) | [(2.80)](/filings/0001956827-26-000012.md) | [(4.83)](/filings/0001956827-26-000012.md) | | Free cash flow | $m | [(45.1)](/filings/0001956827-24-000007.md) | [(54.2)](/filings/0001956827-25-000010.md) | [(97.4)](/filings/0001956827-26-000012.md) | [(155)](/filings/0001956827-26-000012.md) | [(161)](/filings/0001956827-26-000012.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/abvx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $800.6m | 6,007,834 | | Reduced −473,251 | | [Helikon Investments Ltd](/funds/1839497.md) | 2026-06-30 | $371.4m | 2,787,131 | | Added +1,773,807 | | [Darwin Global Management, Ltd.](/funds/1839209.md) | 2026-06-30 | $348.2m | 3,621,583 | | Added +152,926 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $327.7m | 2,458,800 | Call | Added +1,932,900 | | [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $313.1m | 2,349,443 | | Added +849,443 | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $255.1m | 1,913,933 | | Not compared | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $245.9m | 1,844,918 | | Reduced −2,702,488 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $240.5m | 1,804,703 | | Added +410,684 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $213.9m | 1,604,800 | Call | Added +1,136,400 | | [Caligan Partners LP](/funds/1727492.md) | 2026-06-30 | $207.6m | 1,557,924 | | Added +96,000 | ## Recent filings [All 103 filings](/companies/abvx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-21 | 16:12 ET | [6-K](/filings/0001956827-26-000027.md) | Report of a foreign private issuer, period 2026-06-30 | 0001956827-26-000027 | | 2026-07-06 | 21:35 ET | [SCHEDULE 13D/A](/filings/0001104659-26-080877.md) | Ownership report, active investor, amended | 0001104659-26-080877 | | 2026-07-02 | 16:09 ET | [6-K](/filings/0001193125-26-294514.md) | Report of a foreign private issuer, period 2026-07-02 | 0001193125-26-294514 | | 2026-06-29 | 17:22 ET | [6-K](/filings/0001193125-26-288752.md) | Report of a foreign private issuer, period 2026-06-29 | 0001193125-26-288752 | | 2026-06-02 | 06:01 ET | [6-K](/filings/0001193125-26-252360.md) | Report of a foreign private issuer, period 2026-06-01 | 0001193125-26-252360 | | 2026-05-22 | 16:12 ET | [6-K](/filings/0001956827-26-000022.md) | Report of a foreign private issuer, period 2026-03-31 | 0001956827-26-000022 | | 2026-05-20 | 16:47 ET | [6-K](/filings/0001956827-26-000017.md) | Report of a foreign private issuer, period 2026-05-20 | 0001956827-26-000017 | | 2026-05-11 | 12:50 ET | [SCHEDULE 13D/A](/filings/0001104659-26-058492.md) | Ownership report, active investor, amended | 0001104659-26-058492 | | 2026-05-07 | 16:03 ET | [6-K](/filings/0001193125-26-211853.md) | Report of a foreign private issuer, period 2026-05-07 | 0001193125-26-211853 | | 2026-04-20 | 16:07 ET | [6-K](/filings/0001956827-26-000014.md) | Report of a foreign private issuer, period 2026-04-20 | 0001956827-26-000014 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001956827-26-000012.md), filed Mar 23, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1956827 - Tickers: ABVX, AAVXF - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: I0 - Filer category: Accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.